Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan

BMC Health Services Research

Volumn 8, Issue , 2008, Pages

  Liu, Pang Hsiang ^a,b   Wang, Jung Der ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG USE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRESCRIPTION; TAIWAN; TREND STUDY; CLINICAL PRACTICE; COMORBIDITY; DRUG COMBINATION; ECONOMICS; MIDDLE AGED; PRACTICE GUIDELINE; SEX DIFFERENCE; STATISTICS;

ANTIHYPERTENSIVE AGENTS; COMORBIDITY; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTIONS, DRUG; SEX FACTORS; TAIWAN;

EID: 46649121484     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-8-133     Document Type: Article

References (35)

1. Selected major risk factors and global and regional burden of disease. M Ezzati AD Lopez A Rodgers S Vander Hoorn CJ Murray, Lancet 2002 360 1347 1360 10.1016/S0140-6736(02)11403-6 12423980
2. The economic impact of hypertension. WJ Elliott, J Clin Hypertens 2003 5 3 13 10.1111/j.1524-6175.2003.02463.x
3. Hypertension treatment and control in five European countries, Canada, and the United States. K Wolf-Maier RS Cooper H Kramer JR Banegas S Giampaoli MR Joffres N Poulter P Primatesta B Stegmayr M Thamm, Hypertension 2004 43 10 17 10.1161/01.HYP.0000103630.72812.10 14638619
4. High prevalence and poor control of hypertension in primary care: cross-sectional study. AM Sharma HU Wittchen W Kirch D Pittrow E Ritz B Goke H Lehnert D Tschope P Krause M Hofler H Pfister P Bramlage T Unger, J Hypertens 2004 22 479 486 10.1097/00004872-200403000-00009 15076152
5. Diabetes, hypertension, and cardiovascular disease: an update. JR Sowers M Epstein ED Frohlich, Hypertension 2001 37 1053 1059 11304502
6. The progression from hypertension to congestive heart failure. D Levy MG Larson RS Vasan WB Kannel KK Ho, JAMA 1996 275 1557 1562 10.1001/jama.275.20. 1557 8622246
7. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. RB Singh IL Suh VP Singh S Chaithiraphan P Laothavorn RG Sy NA Babilonia AR Rahman S Sheikh B Tomlinson N Sarraf-Zadigan, J Hum Hypertens 2000 14 749 763 10.1038/sj.jhh.1001057 11095165
8. Cause of Death Statistics. Department of Health (Taiwan), http://www.doh.gov.tw/ufile/doc/causesofdeath.pdf
9. Quality of antihypertensive drug therapy at outpatient clinics. Bureau of National Health Insurance (Taiwan), http://www.nhi.gov.tw/webdata/AttachFiles/ Attach_2193_2_hypertension.pdf (in Chinese, accessed on 16 April 2007)
10. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999 17 151 183 10067786
11. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. AV Chobanian GL Bakris HR Black WC Cushman LA Green JL Izzo Jr DW Jones BJ Materson S Oparil JT Wright Jr EJ Roccella, JAMA 2003 289 2560 2572 10.1001/jama.289.19.2560 12748199
12. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. European Society of Hypertension-European Society of Cardiology Guidelines Committee, J Hypertens 2003 21 1011 1053 10.1097/00004872-200306000-00001 12777938
13. Essential hypertension: managing adult patients in primary care. National Institute for Health and Clinical Excellence, http://www.nice.org.uk/nicemedia/ pdf/CG18background.pdf
14. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. B Williams NR Poulter MJ Brown M Davis GT McInnes JF Potter PS Sever SM Thom, BMJ 2004 328 634 640 15016698 10.1136/bmj.328.7440.634
15. Management of hypertension in adults in primary care: partial update. National Institute for Health and Clinical Excellence, http://www.nice.org.uk/ guidance/CG34/guidance/pdf/English
16. Reducing costs and improving compliance. WW Neal, Am J Cardiol 1989 63 17B 20B 10.1016/0002-9149(89)90933-8 2643288
17. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. BM Psaty T Lumley CD Furberg G Schellenbaum M Pahor MH Alderman NS Weiss, JAMA 2003 289 2534 2544 10.1001/jama.289.19.2534 12759325
18. A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. J Mason M Eccles N Freemantle M Drummond, Health Policy 1999 47 37 52 10.1016/S0168-8510(99)00007-X 10387809
19. Antihypertensive drug treatment in a Swedish community: Skaraborg Hypertension and Diabetes Project. E Bog-Hansen U Lindblad J Ranstam A Melander L Rastam, Pharmacoepidemiol Drug Saf 2002 11 45 54 10.1002/pds.681 11998551
20. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. J Ma KV Lee RS Stafford, Hypertension 2006 48 846 852 10.1161/01.HYP.0000240931.90917.0c 16982967
21. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. NR Campbell K Tu R Brant M Duong-Hua FA McAlister, Hypertension 2006 47 22 28 10.1161/01.HYP.0000196269.98463.fd 16344380
22. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. D Siegel J Lopez, JAMA 1997 278 1745 1748 10.1001/jama.278.21.1745 9388150
23. How well have practices followed guidelines in prescribing antihypertensive drugs: the role of health insurance. JD Guo GG Liu DB Christensen AZ Fu, Value Health 2003 6 18 28 10.1046/j.1524-4733.2003.00212.x 12535235
24. Expenditure for Health, 1991-2005. Department of Health (Taiwan), http://www.doh.gov.tw/ufile/doc/9401.xls
25. Pharmacoeconomic burden of undertreating hypertension. L Degli Esposti G Valpiani, Pharmacoeconomics 2004 22 907 928 10.2165/00019053-200422140-00002 15362928
26. Is cost-effectiveness analysis necessary for national health insurance? LJ Cheng JD Wang, J Formos Med Assoc 2006 105 1031 1035 17185248
27. Essential Statistical Data of National Health Insurance. Department of Health (Taiwan), http://www.doh.gov.tw/statistic/english/5-2/1.xls
28. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. JA Whitworth, J Hypertens 2003 21 1983 1992 10.1097/00004872-200311000-00002 14597836
29. Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. T Walley AK Duggan AR Haycox CJ Niziol, J R Soc Med 2003 96 525 531 14594958 10.1258/jrsm.96.11.525
30. International variation in prescribing antihypertensive drugs: its extent and possible explanations. A Fretheim AD Oxman, BMC Health Serv Res 2005 5 21 15762983 10.1186/1472-6963-5-21
31. The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. A Fretheim M Aaserud AD Oxman, BMC Health Serv Res 2003 3 18 12959644 10.1186/1472-6963-3-18
32. Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension. KT Xu M Moloney S Phillips, Am J Manag Care 2003 9 529 536 12921230
33. Trends in pharmacologic management of hypertension in the United States. TA Manolio JA Cutler CD Furberg BM Psaty PK Whelton WB Applegate, Arch Intern Med 1995 155 829 837 10.1001/archinte.155.8.829 7717791
34. Trends in antihypertensive drug advertising, 1985-1996. TJ Wang JC Ausiello RS Stafford, Circulation 1999 99 2055 2057 10209012
35. Do drug company promotions influence physician behavior? B Goodman, West J Med 2001 174 232 233 11290664 10.1136/ewjm.174.4.232